Zeitschrift fur Gastroenterologie最新文献

[Prevention in Gastroenterology]. [胃肠病学预防]。

IF 1.6 4区医学

Zeitschrift fur Gastroenterologie Pub Date : 2026-04-21 DOI: 10.1055/a-2697-3893

Petra Lynen Jansen, Patrick Michl, Thomas Rösch, Britta Siegmund, Thomas Seufferlein, Frank Tacke, Heiner Wedemeyer

{"title":"[Prevention in Gastroenterology].","authors":"Petra Lynen Jansen, Patrick Michl, Thomas Rösch, Britta Siegmund, Thomas Seufferlein, Frank Tacke, Heiner Wedemeyer","doi":"10.1055/a-2697-3893","DOIUrl":"https://doi.org/10.1055/a-2697-3893","url":null,"abstract":"Abstract: Gastroenterology offers a broad, evidence-based range of preventive measures that goes beyond colorectal cancer screening. As a specialty of systemic relevance, it plays a key role in preventing, detecting, and controlling severe diseases - from colorectal and liver cancer to pancreatic, esophageal, and gastric cancers. Preventive strategies include lifestyle interventions, structured screening programs, vaccination approaches, and targeted early detection in high-risk groups. The success of statutory programs such as colorectal cancer and hepatitis screening highlights the potential of early interventions. However, gaps remain between the evidence-based recommendations of the DGVS guidelines and clinical practice. There is also a substantial need for further research, particularly in developing risk-adapted prevention strategies, innovative diagnostic tools, and in harnessing health data and artificial intelligence. A coordinated, cross-sector prevention strategy is essential to structurally anchor and further advance gastroenterological prevention. The declaration of a \"National Decade for Prevention\" would represent a logical continuation of the National Decade Against Cancer - fully leveraging the preventive potential of gastroenterology for the benefit of patients and the healthcare system.","PeriodicalId":23853,"journal":{"name":"Zeitschrift fur Gastroenterologie","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2026-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147783112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Therapy Persistence and Dose Escalation of Advanced Treatments in First and Second Line of Ulcerative Colitis and Crohn's Disease - A Retrospective Cohort Analysis of Healthcare Claims Data. 溃疡性结肠炎和克罗恩病一线和二线先进治疗的治疗持续性和剂量递增——医疗保健索赔数据的回顾性队列分析

IF 1.6 4区医学

Zeitschrift fur Gastroenterologie Pub Date : 2026-04-21 DOI: 10.1055/a-2836-5222

Axel Dignass, Niels Teich, Stephan Kaiser, Juliane Sünwoldt, Evelyn Reinhard, Julia Borchert, Robert Kudernatsch

{"title":"Therapy Persistence and Dose Escalation of Advanced Treatments in First and Second Line of Ulcerative Colitis and Crohn's Disease - A Retrospective Cohort Analysis of Healthcare Claims Data.","authors":"Axel Dignass, Niels Teich, Stephan Kaiser, Juliane Sünwoldt, Evelyn Reinhard, Julia Borchert, Robert Kudernatsch","doi":"10.1055/a-2836-5222","DOIUrl":"https://doi.org/10.1055/a-2836-5222","url":null,"abstract":"Background: There is limited data on advanced therapy outcomes in second-line vs. first-line advanced treatment of patients with ulcerative colitis (UC) and Crohn's disease (CD).Methods: We conducted a retrospective health claims study of patients with UC and CD in Germany. We analyzed claims data from 2014 to 2021, and compared therapy persistence and dose escalation in first- (1L) and second-line (2L) advanced therapy. Our analysis included the approved therapies adalimumab (ADA), infliximab (IFX), ustekinumab (UST) and vedolizumab (VDZ) for both UC and CD patients and golimumab (GOL) and tofacitinib (TOF) for UC patients.Results: 2,948 patients were included in the study and initiated 1L advanced therapy. Of these, 823 patients started a 2L advanced therapy. Time on treatment was generally shorter in 2L compared to 1L: In UC patients, persistence rates at 2 years ranged from 52.5% to 71.9% for 1L, and from 40.1% to 69.1% for 2L. In CD patients, persistence rates ranged from 66.6% to 86.6% for 1L, and from 59.9% to 74.3% for 2L. We observed more frequent dose escalations in 2L than in 1L for all advanced therapies except GOL in UC patients.Conclusions: Our study indicates that advanced therapies have shorter persistence and require higher doses when used as 2L treatment compared to 1L treatment. Future studies on reliable response predictors in patients with UC or CD receiving advanced treatments are likely to improve the selection of more efficacious 1L therapy.","PeriodicalId":23853,"journal":{"name":"Zeitschrift fur Gastroenterologie","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2026-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147783100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Hyperlipasemia following therapy with direct antiviral drugs in patients with chronic hepatitis C virus infection - data from the German Hepatitis C Registry (DHC-R)]. [直接抗病毒药物治疗慢性丙型肝炎病毒感染患者的高脂血症-来自德国丙型肝炎登记处（DHC-R）的数据]。

IF 1.6 4区医学

Zeitschrift fur Gastroenterologie Pub Date : 2026-04-01 Epub Date: 2026-04-22 DOI: 10.1055/a-2769-3946

Bernd Heinrich, Peter Buggisch, Gerlinde Teuber, Albrecht Stoehr, Stefan Christensen, Stefan Mauss, Christoph Sarrazin, Thomas Berg, Heiner Wedemeyer

{"title":"[Hyperlipasemia following therapy with direct antiviral drugs in patients with chronic hepatitis C virus infection - data from the German Hepatitis C Registry (DHC-R)].","authors":"Bernd Heinrich, Peter Buggisch, Gerlinde Teuber, Albrecht Stoehr, Stefan Christensen, Stefan Mauss, Christoph Sarrazin, Thomas Berg, Heiner Wedemeyer","doi":"10.1055/a-2769-3946","DOIUrl":"https://doi.org/10.1055/a-2769-3946","url":null,"abstract":"Abstract: Hyperlipasemia frequently occurs in liver diseases. Alcohol consumption, diabetes, and medications can influence blood lipase levels. The aim of this registry study was to investigate the effect of direct-acting antiviral agents (DAAs) on the frequency of hyperlipasemia in patients with hepatitis C virus (HCV) infection. In addition, alcohol consumption and the diagnosis of diabetes mellitus were considered as influencing factors.Lipase levels of patients from the German Hepatitis C Registry (2014-2022) were retrospectively analyzed. Values below 60 U/L were considered normal. Hyperlipasemia was categorized as \"mild,\" \"moderate,\" or \"severe.\" Patients were grouped according to alcohol consumption (\"none,\" \"low,\" or \"high\") or the presence of diabetes mellitus.Before DAA therapy, 17.2 % of patients showed elevated lipase levels. After therapy, the frequency of hyperlipasemia decreased, reaching a minimum of 12.1 % in year 6 after treatment. Patients with low alcohol consumption showed the lowest rate of hyperlipasemia. Diabetes was associated with elevated lipase levels. Severe hyperlipasemia occurred more frequently at the end of therapy but was overall rare and clinically inapparent. CONCLUSION: Hyperlipasemia is common in HCV infection. Heavy alcohol consumption and diabetes are additional risk factors for hyperlipasemia. An effect of DAA therapy on the prevalence of hyperlipasemia is possible. Further influencing factors, including lifestyle, medication use, or organ dysfunction, need to be investigated to establish causality. Measurement of blood lipase levels without a specific clinical indication should be critically questioned, and results must always be interpreted within the overall clinical context.","PeriodicalId":23853,"journal":{"name":"Zeitschrift fur Gastroenterologie","volume":"64 4","pages":"346-352"},"PeriodicalIF":1.6,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147783226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Use of teduglutide in short bowel syndrome in infants, children and adolescents: Position paper of the working group "Chronic intestinal failure" of the Society for Paediatric Gastroenterology and Nutrition (GPGE)]. [在婴儿、儿童和青少年短肠综合征中使用特杜葡肽：儿科胃肠病学和营养学会（GPGE）“慢性肠衰竭”工作组的立场文件]。

IF 1.6 4区医学

Zeitschrift fur Gastroenterologie Pub Date : 2026-04-01 Epub Date: 2026-02-11 DOI: 10.1055/a-2757-3525

Carsten Posovszky, Jan de Laffolie, Stephan Henning, Antje Ballauf, Jens Berrang, Victor Bildheim, Gunter Burmester, Andreas Entenmann, Gunter Matthias Christian Flemming, Judith Garino, Sebastian Gillmeister, Kathrin Krohn, Corinne Legeret, Eberhard Lurz, Steffen Reinsch, Franziska Righini-Grunder, Aline Rückel, Martina Kohl-Sobania, Johannes Hilberath

{"title":"[Use of teduglutide in short bowel syndrome in infants, children and adolescents: Position paper of the working group \"Chronic intestinal failure\" of the Society for Paediatric Gastroenterology and Nutrition (GPGE)].","authors":"Carsten Posovszky, Jan de Laffolie, Stephan Henning, Antje Ballauf, Jens Berrang, Victor Bildheim, Gunter Burmester, Andreas Entenmann, Gunter Matthias Christian Flemming, Judith Garino, Sebastian Gillmeister, Kathrin Krohn, Corinne Legeret, Eberhard Lurz, Steffen Reinsch, Franziska Righini-Grunder, Aline Rückel, Martina Kohl-Sobania, Johannes Hilberath","doi":"10.1055/a-2757-3525","DOIUrl":"10.1055/a-2757-3525","url":null,"abstract":"Abstract: Paediatric short bowel syndrome (SBS) with chronic intestinal failure (IF) is a rare, complex and potentially life-threatening condition. The main causes in children are necrotizing enterocolitis, volvulus, congenital malformations, and other enteropathies. The resulting reduced intestinal absorption capacity often requires parenteral nutrition (PN), which is associated with complications such as catheter infections, liver disease, and thrombosis, as well as significant limitations in quality of life. The goal of multidisciplinary treatment is to achieve enteral autonomy, prevent complications, and improve quality of life. With the introduction of the glucagon-like peptide-2 analogue (GLP-2-analogue) teduglutide, an additional therapeutic option is available that can improve fluid and nutrient absorption and reduce the need for parenteral support, up to partial or complete weaning. This position paper summarizes the current evidence on the efficacy and safety of teduglutide in children and provides practice-oriented recommendations from the expert group on the following aspects: Definition of relevant treatment goals (e.g., infusion-free days, enteral autonomy), criteria for indication, classification in the treatment algorithm, requirements for education, care, monitoring, and follow-up. The aim is to create a structured framework for the clinical use of teduglutide in children and adolescents.","PeriodicalId":23853,"journal":{"name":"Zeitschrift fur Gastroenterologie","volume":" ","pages":"372-385"},"PeriodicalIF":1.6,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13102493/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146167015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Verrucous esophageal lesion]. [食道疣状病变]。

IF 1.6 4区医学

Zeitschrift fur Gastroenterologie Pub Date : 2026-04-01 Epub Date: 2026-04-22 DOI: 10.1055/a-2741-4101

Sebastian Zundler, Katharina Erlenbach-Wünsch, Jürgen Siebler

引用次数: 0

[Amendment "Resmetirom" to the S2k guideline "Metabolic Liver Diseases" (formerly "Non-Alcoholic Fatty Liver Disease" v.2.0/April 2022) of the German Society for Gastroenterology, Digestive and Metabolic Diseases (DGVS) (Version 2.3)]. [对德国胃肠病学、消化和代谢疾病学会（DGVS）（2.3版）S2k指南“代谢性肝病”（原“非酒精性脂肪性肝病”v.2.0/ 2022年4月）的“Resmetirom”修正案]。

IF 1.6 4区医学

Zeitschrift fur Gastroenterologie Pub Date : 2026-04-01 Epub Date: 2026-04-22 DOI: 10.1055/a-2769-2397

Elke Roeb, Ali Canbay, Heike Bantel, Andreas Geier, Wolf P Hofmann, Michael Roden, Jörn M Schattenberg, Norbert Stefan, Frank Tacke

引用次数: 0

Micro-GIST with BRAF mutation arising in a Leiomyoma: a rare case report and literature review. 平滑肌瘤微间质瘤合并BRAF突变：罕见病例报告及文献复习。

IF 1.6 4区医学

Zeitschrift fur Gastroenterologie Pub Date : 2026-04-01 Epub Date: 2026-04-22 DOI: 10.1055/a-2790-2626

Yongping Zhang, Xuanhao Lin, Xifeng Chen, Chunnian Wang, Ruibing Su

{"title":"Micro-GIST with BRAF mutation arising in a Leiomyoma: a rare case report and literature review.","authors":"Yongping Zhang, Xuanhao Lin, Xifeng Chen, Chunnian Wang, Ruibing Su","doi":"10.1055/a-2790-2626","DOIUrl":"https://doi.org/10.1055/a-2790-2626","url":null,"abstract":"Background: Gastrointestinal stromal tumors (GISTs) are the most common soft tissue tumors of the digestive tract, originating from the interstitial cells of Cajal (ICCs). They are typically characterized by mutations in KIT or PDGFRA genes. However, a subset of GISTs lacks these mutations and has been associated with alternative molecular events. This study presents a case of micro-GIST with a BRAF mutation within a leiomyoma, a rare occurrence with only one previous case reported in the literature involving a C-KIT mutation.Case presentation: A 60-year-old female patient was diagnosed with a gastric submucosal tumor following gastroscopy and upper abdominal ultrasound examinations. The tumor, measuring 1.6 cm × 1.2 cm, was resected via laparoscopic wedge resection. Histological examination revealed a region within the tumor with higher cell density and distinctive cytological features, consistent with GIST. Immunohistochemical analysis confirmed an ICC-like phenotype in this region. NGS identified a BRAF mutation in the dense intermediate cells, while no mutations were found in the surrounding typical leiomyoma region. The patient remained in a satisfactory condition post-surgery.Conclusions: This case report describes the first documented micro-GIST with a BRAF mutation arising in a leiomyoma, highlighting the importance of molecular detection in the differential diagnosis of GISTs.","PeriodicalId":23853,"journal":{"name":"Zeitschrift fur Gastroenterologie","volume":"64 4","pages":"366-371"},"PeriodicalIF":1.6,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147783170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of Living Donor Liver Transplantation in Germany: Opportunities for Expanding the Donor Pool. 德国活体肝移植的评估：扩大供体池的机会。

IF 1.6 4区医学

Zeitschrift fur Gastroenterologie Pub Date : 2026-04-01 Epub Date: 2026-04-22 DOI: 10.1055/a-2769-4047

Oliver Rohland, Felix Dondorf, Laura Schwenk, Aladdin Ali-Deeb, Michael Ardelt, Christina Malessa, Utz Settmacher, Falk Rauchfuß

{"title":"Evaluation of Living Donor Liver Transplantation in Germany: Opportunities for Expanding the Donor Pool.","authors":"Oliver Rohland, Felix Dondorf, Laura Schwenk, Aladdin Ali-Deeb, Michael Ardelt, Christina Malessa, Utz Settmacher, Falk Rauchfuß","doi":"10.1055/a-2769-4047","DOIUrl":"https://doi.org/10.1055/a-2769-4047","url":null,"abstract":"Background: Living donor liver transplantation (LDLT) represents an important alternative to deceased donor transplantation, particularly in times of organ shortage. This study analyzes the selection process of living liver donors at a German transplant center that performs both living and deceased donor liver transplantations.Methods: In a retrospective analysis, potential living liver donors were evaluated. Medical data and reasons for donor exclusion were collected, and recipient cohorts were categorized according to transplantation indication and urgency. Donor outcomes were also assessed.Results: Between January 2013 and December 2023, a total of 594 potential living donors were evaluated at Jena University Hospital. Of these, 124 successfully proceeded to donation. During the outpatient evaluation phase, 357 donors were excluded. Subsequently, 237 individuals underwent inpatient assessments, of whom an additional 100 were excluded. The main reasons for donor exclusion were medical or psychological contraindications (n = 160), as well as donor-independent factors such as disease progression in the recipient (n = 90) or withdrawal of consent by either the recipient or the donor (n = 54). Particularly among recipients with malignant diseases who had little or no chance of receiving a deceased donor organ, a high willingness to donate was observed-even among distant relatives or unrelated donors.Conclusion: A standardized evaluation protocol improves the efficiency of living donor liver transplantation within the Eurotransplant region and ensures donor safety. Diverse contraindications necessitate targeted exclusion diagnostics for individual potential donors.","PeriodicalId":23853,"journal":{"name":"Zeitschrift fur Gastroenterologie","volume":"64 4","pages":"353-365"},"PeriodicalIF":1.6,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13102492/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147783198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effective Management of Esophageal Variceal Hemorrhage Complicated by Ulcerative Reflux Esophagitis Using Over-the-Scope Clip (OTSC) Following Failed Band Ligation: A Case Report. 食管静脉曲张出血合并溃疡性反流性食管炎结扎失败后使用镜外夹（OTSC）的有效治疗：1例报告

IF 1.6 4区医学

Zeitschrift fur Gastroenterologie Pub Date : 2026-03-24 DOI: 10.1055/a-2814-8302

Thomas Balanis, Brindusa Diaconu, Radu Tutuian, Felix Brunner

引用次数: 0

[Endoscopic full-thickness resection (EFTR) of a symptomatic submucosal lesion in the terminal ileum using the full-thickness resection device (FTRD).] [采用全层切除装置（FTRD）对回肠末段症状性粘膜下病变进行内镜全层切除（EFTR）。]

IF 1.6 4区医学

Zeitschrift fur Gastroenterologie Pub Date : 2026-03-24 DOI: 10.1055/a-2822-0801

Richard F Knoop, Golo Petzold, André Sasse, Albrecht Neesse, Volker Ellenrieder, Ahmad Amanzada

{"title":"[Endoscopic full-thickness resection (EFTR) of a symptomatic submucosal lesion in the terminal ileum using the full-thickness resection device (FTRD).]","authors":"Richard F Knoop, Golo Petzold, André Sasse, Albrecht Neesse, Volker Ellenrieder, Ahmad Amanzada","doi":"10.1055/a-2822-0801","DOIUrl":"https://doi.org/10.1055/a-2822-0801","url":null,"abstract":"Endoscopic full-thickness resection (EFTR) with the full-thickness resection device (FTRD) is established for the use in the colon and rectum, offering an effective method for the complete resection of submucosal lesions, e.g. We present the case of a symptomatic 36-year-old patient who was referred to our clinic for an ileocecal resection after a submucosal lesion in the terminal ileum was detected during an external ileocolonoscopy. Prior to the originally planned surgery, our surgical colleagues requested an ileocolonoscopy in domo for precise characterization and endoluminal marking. This confirmed a 15 mm partially lumen-obstructing submucosal lesion in the terminal ileum. The lesion was presented to the surgical team and could be well positioned within the FTRD prOVE Cap. An interdisciplinary consensus for EFTR was reached, which was performed successfully after careful preparation with coagulation marking. Histopathological examination of the full-thickness resection specimen revealed a large lipoma without evidence of malignancy. Although navigating the right hemicolon and ileocecal valve with the FTRD can be challenging, EFTR represents an elegant option for oncologically exact endoluminal resection in selected cases, even in the terminal ileum.","PeriodicalId":23853,"journal":{"name":"Zeitschrift fur Gastroenterologie","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2026-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147515317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0